We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will ...

A new class of weight-loss drugs touted as a revolutionary breakthrough in obesity management have received global attention, ...

The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...

For Swiss policymakers confronting the franc’s strongest levels in almost a decade, there’s comfort to be had: its squeeze on ...

Here are some of the major companies whose stocks moved on the week’s news.

Whether millions gain access to breakthrough anti-obesity treatments may depend on Kennedy, Mehmet Oz and other key players ...

The ESMP platform enables marketing authorisation holders to report shortages and will be mandatory from 2025.

Few companies garner as much reliable attention as Novo Nordisk (NYSE: NVO) does these days. With a bull market coinciding ...

The funds will help Cradle scale its operations to accelerate the adoption of its core product --- an AI-powered protein engineering platform --- designed to ...

A diabetologist and consultant endocrinologist, Prof. Olufemi Fasanmade, has said that over 55,000 Nigerians are estimated to have died from diabetes in 2024.

Amgen's experimental weight loss injection, MariTide, showed up to 20% weight loss in patients without diabetes and 17% in ...

Canada's health regulator has approved Novo Nordisk's weight-loss drug Wegovy to reduce the risk of nonfatal heart attack or ...